Understanding Elevated Lipoprotein(a): A Focus on Cardiovascular Risk and Screening RecommendationsByLibbi Green, PharmDMarch 8th 2024
A Real-World Study of Patients With ASCVD Demonstrates Prevalence of High LDL-C, Demographic Disparities, and Underutilization of Lipid-Lowering TherapyByErin Garrow, PhDMarch 8th 2024
Exploring Patterns in Lp(a) Testing and Lipid-Lowering Therapy Prescription Across 5 Major US Health Systems in Patients With Atherosclerotic Cardiovascular DiseaseByDorothy Cooperson ViewegMarch 8th 2024
Insights Into Lipoprotein(a) Screening Trends: Analysis of a Comprehensive US Health Care Dataset ByAmanda Meyer, MSMarch 8th 2024
Elevated Lipoprotein(a) Increases Cardiovascular Risk Independently of SMuRFsByAmanda Meyer, MSMarch 8th 2024
Examining Low Rates of Real-World Lp(a) Testing: Insights From a Decade-Long Cohort Study in a Diverse Health SystemByDorothy Cooperson ViewegMarch 8th 2024
Prospective Atherosclerosis Risk in Communities (ARIC) Study Connects Differences in Lipoprotein(a) With Racial Disparities in Atherosclerotic Cardiovascular DiseaseByErin Garrow, PhDMarch 8th 2024
